MedTrace Logo

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

NCT01226901 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2012-06-28

No results posted yet for this study

Summary

This study will evaluate whether oral administration of MK-4827 to participants with advanced solid tumors is generally safe and well tolerated.

Conditions

Interventions

DRUG

MK-4827

MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-02-28
Completion
2011-11-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01226901 on ClinicalTrials.gov